Dermata Therapeutics reports Q2 2024 results; DMT310 Phase 3 trial enrollment over 50%

Dermata Therapeutics, Inc.

2025-Q2 EPS reported -$106.44 vs consensus -$2.96 ▼ miss (-3498.4%)

Net cash $4.9M at June 30, 2024, down from $7.4M at Dec 31, 2023; expects to fund ops into Q4 2024.
Raised $2.3M in net proceeds from May 2024 warrant inducement financing.
R&D expenses $2.0M in Q2 2024 vs. $0.8M in Q2 2023 due to STAR-1 trial costs.
DMT310 Phase 3 STAR-1 trial enrolled over 50% of patients; topline data expected Q1 2025.
DMT410 partnership discussions ongoing for topical botulinum toxin delivery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.